| Name | Title | Contact Details |
|---|
Introducing QXO.
We arent your typical cookie-cutter insurance agency. We are privately owned and obsessed with serving our customers and our employees to the very best of our ability. We have the know-how to expertly manage risk, assets, and compliance and the grit to get the job done. Our team is made up of the brightest and most hardworking folks in the insurance industry. Were a bunch of misfits taking care of business every day. Let us know how we can take care of you.
Full Swing is the worldwide leader in cutting-edge indoor golf simulation technology. Full Swing simulators are in the homes of top Tour Pros including Tiger Woods, Jordan Spieth, Jason Day, Jim Furyk, Padraig Harrington, Smylie Kaufman, and many more. Our patented dual tracking technology delivers superior ball tracking data and makes Full Swing the only simulator that actually measures ball flight indoors. With over 30 years of experience, Full Swing provides the most accurate and realistic golf experience you can find. From practice to instruction, to entertainment, this is the world-class experience youve been looking for. For further information, please visit www.fullswinggolf.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.